FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

49
FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice Julie Burke TC1600 Quality Assurance Specialist 571-272-0512 [email protected] October 2009

description

FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice. Julie Burke TC1600 Quality Assurance Specialist 571-272-0512 [email protected]. October 2009. TC 1600 Filings and Restrictions. In FY09, TC1600 mailed 33,191 first Office actions on the merits - PowerPoint PPT Presentation

Transcript of FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Page 1: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

FY09 Restriction Petition Update; Comparison of US and National

Stage Restriction Practice

Julie Burke

TC1600 Quality Assurance Specialist

571-272-0512

[email protected]

October 2009

Page 2: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 2

TC 1600 Filings and Restrictions

In FY09, TC1600 •mailed 33,191 first Office actions on the merits •mailed 11,871 restriction requirements•received about 75 restriction petitions

National stage filings of a PCT application under 371account for 29% of TC1600 applicationsyet result in 34% of the petitions

In FY09 78% of the Restriction Petitions were granted in full or in part 34% of the petitions applications were filed under 35 USC 371

Average restriction petition turn around time about 100 days

Page 3: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 3

Restriction and Unity of Invention Petitions Filed in FY04 – FY09

7570

49

83

61

69

0

10

20

30

40

50

60

70

80

90

2004 2005 2006 (1st plus2nd Qtr.)

2007 2008 2009

Fiscal Year

Nu

mb

er O

f P

etit

ion

s F

iled

Petitions Filed

Page 4: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 4

Restriction in 111 (a) and Unity of Invention in 371 For FY04 - FY09

74

58

71

78

72

65

26

42

29

2228

35

0

10

20

30

40

50

60

70

80

90

FY04 FY05 FY06 FY07 FY08 FY09

Fiscal Year

Per

cen

tag

e

111(a) 371

Page 5: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 5

Restriction Petitions by Workgroup Filed in FY04 to FY09

10

16

20

18

8

5

26

14 14

10

2

20

14

10

3

10

28

1615

14

7

10

19 19

78

25

21

87

0

5

10

15

20

25

30

1610 PharmaceuticalCompositions

1620 PharmaceuticalCompounds

1630 Nucleic Acids 1640 Antibodies 1650 Protein

WorkGroup

Nu

mb

er o

f p

etit

on

s fi

led

FY04 FY05 FY06 FY07 FY08 FY09

Page 6: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 6

Petition Outcome by Fiscal Year

44

38

31

37

53

57

12

2628 29

13

21

38

32

39

31

16

64

2

10

36

24

0

10

20

30

40

50

60

FY04 FY05 FY06 FY07 FY08 FY09

Fiscal Year

Pe

rce

nta

ge

Of

pe

titi

on

s f

iled

Grant Grant In Part Deny Dismissed

Page 7: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 7

Petition Outcome by Workgroup For FY05

5

17

2 2

00

2

5 56

0

76

7

4

0

23

2 2

0

2

4

6

8

10

12

14

16

18

1610 PharmaceuticalCompositions

1620 PharmaceuticalCompounds

1630 Nucleic Acids 1640 Antibodies 1650 Protein

Workgroup

Nu

mb

er o

f p

etit

ion

s fi

led

Grant Grant In Part Deny Dismissed

Page 8: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 8

Petition Outcome by Workgroup For FY06

2

11

1 1 1

0

3

6

4

00

6 6

5

2

0 0

1

0 00

2

4

6

8

10

12

1610 PharmaceuticalCompositions

1620 PharmaceuticalCompounds

1630 Nucleic Acids 1640 Antibodies 1650 Protein

Workgroup

Nu

mb

er

of

pe

titi

on

s f

ile

d

Grant Grant In Part Deny Dismissed

Page 9: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 9

Petition Outcome By Workgroup FY07

4

10

6 6

5

0

11

5

6

3

4 4 4

2

5

2

3

1 1 1

0

2

4

6

8

10

12

1610 PharmaceuticalCompositions

1620 PharmaceuticalCompounds

1630 Nucleic Acids 1640 Antibodies 1650 Protein

Workgroup

Nu

mb

er o

f p

etit

ion

s fi

led

Grant Grant In Part Deny Dismissed

Page 10: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 10

Petition Outcome By Workgroup For FY08

2

4

12

11

3

0

2

1

2

3 3

6

4

22

0 0 0 0

3

0

2

4

6

8

10

12

14

1610 1620 1630 1640 1650

Fiscal Year

Nu

mb

er O

f p

etit

ion

s fi

led

Grant Grant In Part Deny Dismissed

Page 11: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 11

Petition Outcome By Workgroup For FY09

3

18

9

4 4

2

6 6

01

21

43

10 0

21 1

0

2

4

6

8

10

12

14

16

18

20

1610Pharmaceutical

Compositions

1620Pharmaceutical

Compounds

1630 Nucleic Acids 1640 Antibodies 1650 Protein

Work group

Nu

mb

er o

f P

etit

ion

s fi

led

Grant Grant In Part Deny Dismissed

Page 12: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 12

TYPES OF CONCERNS FY04

16

12

17

4

0

4

17

0

2

4

6

8

10

12

14

16

18

Markush 10 Seq/case Burden Linking Claim Rejoinder Distinction GroupingWrong

To

tal

Page 13: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 13

TYPES OF CONCERNS FY05

27

2

10

6

4

7 7

0

5

10

15

20

25

30

Markush 10 Seq/case Burden Linking Claim Rejoinder Distinction GroupingWrong

To

tal

Page 14: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 14

TYPES OF CONCERNS FY06

14

8

7 7

2

3

4

0

2

4

6

8

10

12

14

16

Markush 10 Seq/case Burden Linking Claim Rejoinder Distinction GroupingWrong

To

tal

Page 15: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 15

TYPES OF CONCERNS FY07

21

3

31

9

5

32

8

0

5

10

15

20

25

30

35

Markush 10 Seq/case Burden Linking Claim Rejoinder Distinction GroupingWrong

To

tal

Page 16: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 16

TYPES OF CONCERNS FY08

8

5

10

7

10

15

10

0

2

4

6

8

10

12

14

16

Markush 10 Seq/case Burden Linking Claim Rejoinder Distinction GroupingWrong

To

tal

Page 17: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 17

TYPES OF CONCERNS FY09

18

5

7

11

3

12

5

12

56

7

2

0

2

4

6

8

10

12

14

16

18

20

Mar

kush

10 Seq

/cas

e

Burden

Linkin

g Cla

im

Rejoin

der

Distin

ctio

n

Groupin

g Wro

ng

Product

/Pro

cess

Combin

atio

n/Sub

Combin

atio

n

With

draw b

y Orig

inal

Pre

senta

tion

Already

exam

ined

toget

her

Double

Pate

nting/T

erm

inal

Dis

claim

er

To

tal

Page 18: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 18

Other Outcomes from Petition Decisions in FY09

Previous Office Action on Merits is withdrawn as incomplete 16

Objection to claims for reciting non-elected subject matter is withdrawn.

9

Restriction is turned into a provisional election of species. 6

Notice(s) of non-responsive amendments are replaced with miscellaneous communication regarding bona fide response

4

Number of Petitions

Page 19: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 19

Overview of Common Concerns For FY09

US (111) & National Phase (371) Applications

• Compounds and Compositions• Products and Processes• Rejoinder• Restriction AFTER an Office action on the merits• Election of Species permitted for new claims• Withdrawn via Election by Original Presentation• Requirement to remove non-elected subject matter• Notice of Non-Compliant Amendments versus

Notice of Non-Responsive Amendments • Getting applications back on track

Page 20: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 20

Compounds and Compositions- 111

Claim 1: Compound A.

Claim 2: An insecticide composition comprising Compound A and a carrier.

“Where inventions are related as disclosed but are not distinct as claimed, restriction is never proper.” MPEP 806

“Where the claims of an application define the same essential characteristics of a single disclosed embodiment of an invention, restriction there between should never be required. This is because the claims are not directed to distinct inventions; rather they are different definitions of the same disclosed subject matter, varying in breadth or scope of definition.” MPEP 806.03

Page 21: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 21

Compounds and Compositions- 371

“Claim 1: Compound A.

Claim 2: An insecticide composition comprising compound A and a carrier.

Unity exists between claims 1 and 2. The special technical feature common to all the claims is compound A.”

ISPE Guidelines, Example 15

Page 22: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 22

Products and Processes- 111

Does the process of making or the process of using require the product as claimed?

Tip: does the process claim depend from or otherwise require all the limitations of the product claim?

If yes, then distinction is possible only if the examiner can provide a materially different way to make or to use the product.

MPEP 806.05(f) and (h)

Page 23: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 23

Product & Process Reconsideration - 111

“The burden is on the examiner to provide an example, but the example need not be documented.

If the applicant either proves or provides a convincing argument that the alternative use suggested by the examiner cannot be accomplished, the burden is on the examiner to support a viable alternative use or withdraw the requirement.”

MPEP 806.05(h)

Page 24: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 24

Products and Processes- 371

Does the process of making or the process of using require the product as claimed?

Tip: does the process claim depend from or otherwise require all the limitations of the product claim?

If yes, then lack of unity is possible only if the examiner can provide prior art that anticipates or renders obvious the product, as claimed.

PCT Rule 13.2 and ISPE Guidelines Example 1.

Page 25: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 25

Products and Processes- 371

“Claim 1: A method of manufacturing chemical substance X. Claim 2: Substance X. Claim 3: The (method of) use of substance X as an insecticide.

Unity exists between claims 1, 2 and 3. The special technical feature common to all the claims is substance X.

However, if substance X is known in the art, unity would be lacking because there would not be a special technical feature common to all the claims.”

ISPE Guidelines, Example 1.

Page 26: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 26

Rejoinder Practice Applies to 371s

“If an examiner (1) determines that the claims lack unity of invention and (2) requires election of a single invention, when all of the claims drawn to the elected invention are allowable (i.e., meet the requirements of 35 U.S.C. 101, 102, 103 and 112), the nonelected invention(s) should be considered for rejoinder.

Any nonelected product claim that requires all the limitations of an allowable product claim, and any nonelected process claim that requires all the limitations of an allowable process claim, should be rejoined. See MPEP § 821.04. Any nonelected processes of making and/or using an allowable product should be considered for rejoinder.”

MPEP 1893.05(d)

Page 27: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 27

Rejoinder for 371s and 111s

“The propriety of a restriction requirement should be reconsidered when all the claims directed to the elected invention are in condition for allowance, and the nonelected invention(s) should be considered for rejoinder.

Rejoinder involves withdrawal of a restriction requirement between an allowable elected invention and a nonelected invention and examination of the formerly nonelected invention on the merits.”

MPEP 821.04

Page 28: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 28

Restriction is improper after an Office action on merits- 111 & 371

If the subject matter was already examined together on the merits, it would not be a burden on the examiner to continue to examine the subject matter, even if it is directed to independent and distinct inventions.

MPEP 803: Restriction is permitted only when “There would be a serious burden on the examiner if restriction is not required.”

Page 29: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 29

Example of an Improper Restriction After an Office Action- 111 or 371

Claims 1-10, directed to product and Claims 11-20, directed to a process of using the product, were examined together in a first action on the merits and a final action.

No restriction or election of species had been required.

Applicants filed a Request for Continued Examination and added 5 new product claims 21-25 which depended from claim 1.

The same examiner then set forth a restriction requirement between: Group I, the product, Claims 1-10 and 21-25 and Group II, process of use, Claims 11-20.

This restriction is generally improper, regardless of whether the restriction was required by the same or different examiner.

Page 30: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 30

Full Faith and Credit Given to a Previous Examiners’ Search

“When an examiner is assigned to act on an application which has received one or more actions by some other examiner, full faith and credit should be given to the search and action of the previous examiner unless there is a clear error in the previous action or knowledge of other prior art.

In general the second examiner should not take an entirely new approach to the application or attempt to reorient the point of view of the previous examiner, or make a new search in the mere hope of finding something.”

MPEP § 704.01.

Page 31: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 31

Time to Require Restriction

37 CFR 1.142(a), second sentence, indicates that a restriction requirement

“will normally be made before any action upon the merits; however, it may be made at any time before final action.”

“This means the examiner should make a proper requirement as early as possible in the prosecution, in the first action if possible, otherwise, as soon as the need for a proper requirement develops.

Before making a restriction requirement after the first action on the merits, the examiner will consider whether there will be a serious burden if restriction is not required.”

MPEP 811

Page 32: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 32

Election of Species is Permitted for Newly Added Claims- 111 & 371

“If applicant presents species claims to more than one patentably distinct species of the invention after an Office action on only generic claims, with no restriction requirement, the Office may require the applicant to elect a single species for examination.”

MPEP 808.01

Page 33: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 33

Example of an Election of Species for Newly Added Claims

Claim 1. A composition comprising Compound X and a pain reliever.

Claim 1 was examined and rejected over prior art teaching a composition of Compound X and Aspirin.

In addition to arguments, Applicants add new Claim 2:

Claim 2. (new) The composition of Claim 1 where the pain reliever is morphine, ibuprofen, or novacain.

The examiner may require applicants to elect one of the newly presented species of pain relievers using Form Paragraph 8.01.

MPEP 808.01

Page 34: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 34

Subsequent presentation of claims for different invention

35 U.S.C. 121. Divisional applications.

If two or more independent and distinct inventions are claimed in one application, the Director may require the application to be restricted to one of the inventions….

37 CFR 1.145. Subsequent presentation of claims for different invention.

If, after an office action on an application, the applicant presents claims directed to an invention distinct from and independent of the invention previously claimed, the applicant will be required to restrict the claims to the invention previously claimed….

Emphasis added

Page 35: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 35

Reasons are Required to Restrict Out Newly Added Claims - 111

Form Paragraph 8.04:

“Newly submitted claim [ 1 ] directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: [ 2 ]”

Form Paragraph 8.26

“The remaining claims are not readable on the elected invention because [ 2 ].”

MPEP 821.03

Page 36: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 36

Reasons include Independence, Distinction and Burden - 111

“I. CRITERIA FOR RESTRICTION BETWEEN PATENTABLY DISTINCTINVENTIONS

There are two criteria for a proper requirement for restriction between patentably distinct inventions:

(A) The inventions must be independent (see MPEP § 802.01, §806.06, § 808.01) or distinct as claimed (see MPEP § 806.05 - §806.05(j)); and

(B) There would be a serious burden on the examiner if restriction is not required (see MPEP §  803.02, §   808, and §   808.02.)”

MPEP 803

Page 37: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 37

Reasons are Required to Restrict Out Newly Added Claims - 371

Form Paragraph 18.21:

“Newly submitted claim [ 1 ] directed to an invention that lacks unity with the invention originally claimed for the following reasons:

[ 2]”

MPEP 1893.05(d)

Page 38: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 38

Election By Original Presentation Markush Claims- 111 & 371

Election by original presentation “is not applicable where a provisional election of a single species was made in accordance with MPEP § 803.02 and applicant amends the claims such that the elected species is cancelled.”

MPEP 821.03, last paragraph.

Page 39: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 39

Amended Markush Claim

Claim 1 (original) A composition comprising compound A, compound B or compound C.

The examiner required an election of species. The Applicant provisionally elected Compound A. In the first Office action, the examiner applied prior art that anticipated elected Compound A.

In response, applicants amended claim 1 as follows:

Claim 1 (amended) A composition comprising compound A, compound B or compound C.

The examiner then withdrew Claim 1 from consideration as being directed to a non-elected invention.

The resulting petition to withdraw this requirement was granted. Claim 1 must be examined according to MPEP 821.03.

Page 40: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 40

Election By Original Presentation Non-restrictable Claims- 111 & 371

Election by original presentation is not applicable “where applicant presents claims that could not have been restricted from the claims drawn to the other elected invention had they been presented earlier.”

MPEP 821.03, last paragraph.

Page 41: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 41

New claims that cannot be restricted after an Office Action-111 & 371

Product Claims 1-10 were examined together in a first action on the merits.

Applicants added 5 new product claims 11-15 that depended from and further limited claim 1.

The examiner then withdrew claims 11-15 from consideration citing MPEP 821.03.

Had they been originally filed together, dependent claims 11-15 could not have been properly restricted from the independent claims 1-10.

The resulting petition to withdraw this requirement was granted.

Page 42: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 42

Improper Requirements to Remove Non-Elected Alternatives from Markush Claims

“Following election, the Markush-type claim will be examined fully with respect to the elected species and further to the extent necessary to determine patentability.

Should the examiner determine that the elected species is allowable, the examination of the Markush-type claim will be extended.”

MPEP 803.02

Page 43: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 43

Improper Requirements to Cancel Linked Claims

“Where the requirement for restriction in an application is predicated upon the nonallowability of generic or other type of linking claims, applicant is entitled to retain in the application claims to the nonelected invention or inventions.”

MPEP 809

Page 44: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 44

Improper Requirements to Cancel Potentially Rejoinable Claims

“In order to be eligible for rejoinder, a claim to a nonelected invention must depend from or otherwise require all the limitations of an allowable claim…

In order to retain the right to rejoinder, applicant is advised that the claims to the nonelected invention(s) should be amended during prosecution to require the limitations of the elected invention. Failure to do so may result in a loss of the right to rejoinder.”

MPEP 821.04

Page 45: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 45

Applicants may file new claims to non-elected inventions

“An amendment presenting additional claims that depend from or otherwise require all the limitations of an allowable claim will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier.

Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.”

MPEP 821.04(a)

Page 46: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 46

Getting Applications Back on Track

When a petition is granted, the decision may also address, among other things, whether

• the previous Office action should be withdrawn as incomplete, if improperly withdrawn claims had not been examined;

• claims filed after final should have been entered, if they were improperly refused entry as being directed to a non-elected invention and/or;

• improperly mailed Notice of Non-Compliant Amendments should be vacated.

Page 47: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 47

NNCA versus NNRA

Notice of Non-Compliant Amendment (NNCA)• Amendment format requirements of 37 CFR 1.121• MPEP 714 provide options and leeway• Sent out on a PTOL-324 form

Notice a Non- Responsive Amendment (NNRA)• For otherwise Bona fide response under 37 CFR

1.135(c)• MPEP 714.03 provides options and leeway• Sent out on a PTOL-90 form

Page 48: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Final 12/08/09 48

Getting Applications Back on Track

If there have been extensive delays in prosecution, in order to help ensure compact prosecution, the Supervisory Patent Examiner may be required to review next Office action:

“The supervisory patent examiners are expected to

personally check on the pendency of every application which is up for the third or subsequent Office action with a view to finally concluding its prosecution.”

MPEP 707.02

Page 49: FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice

Questions?

Julie Burke

TC1600 Quality Assurance Specialist

571-272-0512

[email protected]

October 2009